To evaluate the diagnostic accuracy of cardiovascular magnetic resonance (CMR) imaging from a risk-stratification and therapeutic-management perspective in patients with suspected cardiac tumours.
Introduction
Cardiac tumours represent a rare but important cause of morbidity and mortality. 1 -3 The therapeutic management of cardiac masses differs fundamentally according to the nature of the cardiac mass (neoplastic vs. non-neoplastic) and tumour type (benign or malignant, primary or secondary), and furthermore depends on clinical circumstances such as haemodynamic failure, invasive growth, and metastatic spreading, which either prompt for an intervention or rather make it irrational. 1,2 Cardiac magnetic resonance (CMR) imaging is considered the imaging modality of choice for the assessment of cardiac masses. 4 It permits highquality, multiplanar imaging of tumour morphology, tissue composition, and perfusion. Additional assets of CMR are its ability to assess cardiac function, blood flow, and its large field of view that allows visualization of the paracardiac structures and the great vessels. Yet, studies demonstrating clinical advantages are sparse. We conducted a retrospective study to evaluate the diagnostic accuracy of CMR from a patient-management perspective in subjects with suspected cardiac or paracardiac tumours. For this † These authors contributed equally to this work.
purpose, CMR-derived tumour diagnosis was compared with the histological findings of biopsy specimens in patients undergoing surgery or autopsy. In patients declined from surgery based on the CMR diagnosis, the predicted benign character and presumed histology were compared with the clinical follow-up and outcome.
Methods
We retrospectively reviewed the CMR exams of all patients (n ¼ 41) referred between January 2002 and August 2009 for the first evaluation of a cardiac or paracardiac mass, detected or suspected at echocardiography (n ¼ 39) or thoracic computed tomography (CT; n ¼ 2).
Patients with suspicion of thrombus were considered only if the referral question explicitly included tumour as differential diagnosis. Clinical charts were reviewed for patient characteristics, disease symptoms, medical history, and neoplastic disease established prior to initial echocardiography and CMR. Data on disease course and outcome were gathered from the time of CMR diagnosis until the date of study closure (February 2010). Follow-up status was ascertained in all patients by checking hospital records and by contacting the patients' general practitioners with a short questionnaire on vital status, type and date of major cardiovascular events, and last follow-up date. In patients undergoing surgery or autopsy, intra-operative macroscopic and histological findings were also recorded ( Figure 1 ).
Cardiac magnetic resonance imaging protocol
Cardiac magnetic resonance studies were performed on a 1.5 T system equipped with a phased-array body coil (Sonata & Avanto, Siemens, Erlangen, Germany). As a standard CMR protocol for the evaluation of tumours and masses in our institution ('cardiac tumour protocol'), image sequences typically included axial T2-weighted turbo spin echo sequences (T2-TSE) covering the entire thorax and breath-hold segmented steady-state free precession cine imaging sequences in four-chamber and short-axis views. T1-weighted turbo spin echo sequences (T1-TSE) were targeted on the tumour mass. First-pass perfusion images through the lesion and myocardium were acquired by a contrast-enhanced saturation recovery gradient-recalled echo sequence after a bolus of 0.2 mL/kg (0.1 mmol/kg) gadobenate dimeglumine (Multihance, Bracco, Mendrisio, Switzerland) infused at 4 mL/s and followed 10 -15 min later by late gadolinium enhancement (LGE) imaging using a breath-hold inversion-recovery gradient-echo sequence. In addition, early contrast-enhanced T1-TSE, fat-saturated T1-TSE, and/or black blood fat-saturated (triple inversion recovery) T2 spin sequences were added if deemed necessary for further tissue differentiation. 5 All images were acquired under supervision of an experienced (Level III) cardiologist and/or radiologist.
Evaluation and interpretation of cardiac magnetic resonance images
Cardiac magnetic resonance images were retrospectively evaluated during consensus reading sessions by at least one cardiologist and one radiologist, to whom only the referral question was available. Lesions were categorized as neoplastic or non-neoplastic lesions, with the former further differentiated into benign or malignant tumours and the latter into normal variants or non-neoplastic masses, respectively. For suspected neoplastic lesions, a histological diagnosis was postulated according to previously suggested criteria based on a qualitative assessment of tumour morphology and signal intensity in each of the available CMR sequences ( Table 1) . 5 -9 Evaluation of tumour morphology included tumour location, shape and mobility, tumour border definition and/or tissue infiltration, and the presence of pericardial effusion. The tissue composition of a lesion was estimated based on the signal characteristics and qualitatively scored as homogenous or heterogeneous. In addition, in each sequence tumour signal intensity was assessed qualitatively as hypo-, iso-, or hyperintense with reference to the normal myocardium. Finally, tumour vascularization and the presence of interstitial fibrosis or extensive acellular areas within the mass were qualitatively scored as present or absent on first-pass perfusion imaging and delayed contrast-enhanced imaging, respectively.
Statistical analysis and reporting
Statistical analysis was performed using SPSS 15.0 (SPSS Inc., Chicago, IL, USA). Categorical data are summarized as frequencies and percentages; continuous variables are expressed as mean + SD or as median (inter-quartile range) as appropriate. A two-sided P-value of ,0.05 was considered as statistically significant. Differences in CMR characteristics between malignant and benign masses were compared by Fisher's exact test. Survival for patients with tumours stratified by CMR as malignant, benign, or normal variants was compared by log-rank analysis on the Kaplan-Meier survival curves.
Results
The final study population comprised 41 patients (21 men, mean age 61 + 14y), presenting with a mass alleged in echocardiography (n ¼ 39) or incidentally found on a chest CT (n ¼ 2). Presenting symptoms were heart failure (n ¼ 6), stroke (n ¼ 4), syncope (n ¼ 3), acute coronary syndrome (n ¼ 2), and pulmonary embolism (n ¼ 1). In the remaining patients, the mass was revealed accidentally in the context of tumour staging (n ¼ 4) or during elective work-up for weight loss, dyspnoea, hypertension, angina, or arrhythmias. The referral technique postulated the suspected mass to be neoplastic in 23 (56%) patients (malignant/benign: 7/ 15), non-neoplastic in four (10%), and remained uncertain about the nature of the lesion in the remaining 15 (36%) patients. Fourteen patients (34%) had a prior history of non-cardiac malignancy, (haematological malignancy n ¼ 4, bronchus carcinoma n ¼ 3, breast cancer n ¼ 2, and oropharynx, ovarium, prostate, or seminoma each in n ¼ 1), with documentation of non-cardiac metastatic spreading before CMR in four.
Cardiac magnetic resonance-based stratification and patient management
On the basis of the consensus reading of the CMR images, the suspected mass was identified and classified as neoplastic in 23 (56%) and as non-neoplastic or absent in 17 (42%) of the 41 patients. In one patient with a well-perfused and enhancing intramural left atrial mass, the initial CMR was equivocal on the presence of a malignancy or an inflammatory pseudotumour ( Figure 1 ). After serial CMR and clinical assessments under immunosuppressive therapy, vasculitis involving the atrial wall was eventually established as diagnosis. Table 2 lists the main findings in patients with a CMR diagnosis of cardiac neoplasm and/or histological data for comparison. Eight tumours were judged by the CMR experts to be malignant, 14 benign, and in one patient, consensus on the malignancy could not be reached. In the remaining patients, CMR either concluded on the presence of thrombus (n ¼ 2), established the suspected masses as anatomical variants (atypically localized epicardial fat, lipomatous hypertrophy of the interatrial septum, prominent atrial cristae, and localized ventricular hypertrophy, each in 2), or could not detect any mass at all (n ¼ 7). Cardiac magnetic resonance was the ultimate imaging technique used for tumour characterization in all patients. A surgical procedure was proposed as final therapy and histological data were obtained in 18 of the 23 patients with neoplasm, whereas in five, surgery was declined because of evidence for disseminated cancer (n ¼ 3) or for critically localized, benign tumours not justifying a high-risk intervention (n ¼ 2). The latter five patients with and the remaining 18 patients without a neoplastic lesion diagnosed by CMR were managed conservatively with documentation of clinical events (Figures 1 and 2) . Histological information on the nature of the suspected mass in this group thus failed, except for two patients who died and underwent autopsy within 40 days of the initial CMR.
Cardiac magnetic resonance findings compared with histology
In 16 out of 20 cases (80%) with available histopathological data, the CMR features in adjunct to the referral information permitted to classify the masses correctly as 'malignant neoplasm', 'benign neoplasm', or 'no neoplasm' ( Table 2) . Cardiac magnetic resonance experts misclassified two non-neoplastic masses as benign neoplasm and inversely failed to detect a small (8 × 8 mm) fibroelastoma, yielding an accuracy of 17 of 20 (85%) to classify masses correctly as neoplasm or not. One metastasis with extensive myxoid degeneration on gross pathological examination was misclassified as a benign myxoma. Thus, in dichotomizing masses as benign in nature or not, CMR was accurate in 19 of 20 (95%) of all cases. Table 3 summarizes the most useful CMR criteria in the distinction between malignant and benign lesions.
Tissue and/or tumour characteristics on cardiac magnetic resonance Individual signal characteristics of the alleged masses were highly variable. An integrative approach allowing for the interpretation of signal patterns ( Table 1 ) enabled a certain level of virtual histological differentiation that proved helpful in selected clinical scenarios. Some typical patterns are described here.
Normal variants and non-neoplastic masses
In most (10/15, 67%) of the cases where CMR excluded masses (n ¼ 7) or demonstrated anatomic variants that had been interpreted as a possible mass (n ¼ 8), focal wall thickening or extensive epicardial tissue masses had evoked doubt about the presence of an intramural or epicardial tumour. Cardiac magnetic resonance diagnosis was based on the absence of soft tissue contrast in all driven sequences or on the demonstration of excessive fat deposition. Two small valvular lesions irrefutably demonstrated by echocardiography, of which one was histologically confirmed as fibroelastoma, were nevertheless missed. Thrombi (n ¼ 2) were diagnosed based on the presence of an intracavitary mass without perfusion and late enhancement, but typically adjacent to the myocardium displaying delayed enhancement.
10 Figure 3 provides an example in a patient referred with suspicion of apical tumour or hypertrophy.
Lipoma and lipomatous septal hypertrophy Typical for these fatty masses was a homogeneous and hyperintense signal in cine and spin echo sequences, behaving similar to subcutaneous fat in all sequences and displaying signal loss after fat saturation prepulses (Figure 4) . Whereas the lipoma (n ¼ 1) was well defined and partially intramural, lipomatous hypertrophy rather presented as diffuse thickening of the interatrial septum and adjacent posterior right atrial wall, with sparing of the fossa ovalis. Echocardiography remained equivocal about the nature of the mass in all cases, erroneously suggesting metastatic infiltration in one patient (Case 24). Cases grouped according to the presence of a tumour diagnosed by CMR and/or availability of histological data, and by the presence or absence of prior malignancies. M + , known extracardiac metastasis at time of referral; inv.haemangiom, invasive haemangioma; Mult. Myel., multiple myeloma; meta, metastasis; nonprim. card., non-primarily cardiac malignancy of mesenchymal or lymphoid origin; IASH, lipomatous hypertrophy of the interatrial septum; caseus calcification of the mitral annulus; E, equivocal; NN, non-neoplastic; B, benign; M, malignant; NA, not available. a As judged on CMR, intra-operatively, the tumour proved to be attached to the LA roof, not the IAS. cine imaging (A) and T1-weighted turbo spin echo sequences (B), the mass is hypointense in fat-saturated T2-weighted imaging and delineated by a hyperintense rim suggesting oedema (C). Contrary to the myocardium, signal intensity in the mass remains unchanged between the left ventricular phase (D) and the myocardial phase (E) of contrast passage, indicating poor or absent mass perfusion. Accordingly, there is no delayed uptake of contrast within the mass a rim of enhancement compatible with endocardial fibrosis is seen (F ).
Myxoma
All histologically confirmed myxomas (n ¼ 9) were heterogeneous in cine imaging, compatible with regional differences in cellularity and extensive myxoid stroma and with occasional focal necrosis and haemorrhage. Myxomas were typically hyperintense in T2-TSE and isointense in T1-TSE. Signal enhancement during first-pass perfusion and delayed enhancement was detected in 16 and 40% of the cases, respectively ( Figure 5 ). Myxomas were pedunculated, mobile, and attached at the left (78%) or right (11%) interatrial septum. One myxoma (11%) grew in close contact with a pulmonary vein ostium. A thrombus mistaken for myxoma (Case 17) differed from the common pattern by a similar atypical localization (pulmonary vein ostium) and low signal in T2-TSE. A left atrial metastasis with extensive myxoid degeneration at histology had typical signal features of myxoma (Case 4). Nevertheless, clinical suspicion of metastasis was raised by concomitant visualization of pulmonary metastasis.
Malignant tumours (primary and metastasis)
Malignant tumours typically (≥85%) presented on CMR as broadbased bulky masses with invasive or compressive growth and signal heterogeneity. Although not a universal finding, pericardial effusion was a common and highly specific feature ( Table 3) . Sarcomas (n ¼ 3) were hyperintense in T2-TSE, had signal heterogeneity in multiple sequences, and heterogeneous uptake of contrast. All metastases (n ¼ 4) were diagnosed in patients with previously demonstrated extracardiac metastatic spreading. Signal characteristics and contrast enhancement were variable and inconsistent. Compared with the referral technique, CMR diagnosed a primary cardiac sarcoma in a young woman with presumptive diagnosis of an inflammatory mass ( Figure 6 ) and better documented infiltration and local spreading in all cases, aiding operative planning.
Cardiac magnetic resonance findings compared with clinical follow-up
Overall, and considered independently of therapeutic management, 13 deaths occurred over a median observation period of 705 (303-1472) days. All but one of the patients with a malignant tumour diagnosed on CMR died; on average within 377 (76 -819) days. By the Kaplan-Meier analysis, mortality in patients diagnosed by CMR with a benign neoplasm [2/14, within 1160 (408-1650) Figure 4 Septal lipoma. The signal intensity of the intramural tumour is homogeneous and behaves similar to subcutaneous fat in all sequences: the high signal in T1-weighted turbo spin echo sequences (A) is suppressed after a fat-specific saturation pulse (B). There is no detectable contrast uptake on fat-saturated T1-weighted turbo spin echo sequences repeated 10 min after gadolinium administration (C).
Figure 5
Perfusion and late enhancement study of a myxoma. A large mass with attachment to the right-sided interatrial septum is identified.
On first-pass perfusion images taken during the ventricular (A) and myocardial perfusion phase (B), no noticeable perfusion is discerned. Delayed gadolinium enhancement of the tumour is also absent (C ). The diagnosis of myxoma was confirmed at histology. days] was significantly lower than that in those diagnosed with a malignant tumour (P , 0.01) and did not differ from mortality in patients where CMR had concluded that a cardiac mass was either absent or non-neoplastic [3/18 within 745 (286-1492) days]. Of importance, of these five patients dying despite the diagnosis of a benign condition, only one patient (Case 4) was misclassified by CMR, whereas in four, the histological (Cases 6, 24, and 25) or clinical (relapsing empyema) data excluded the suspected mass as cause of death. As such, when considered from the perspective of CMR-guided therapy management ('intention to treat'), no tumour-related deaths occurred in conservatively managed patients other than in those receiving palliative care ( Figure 2) . Inversely, two patients without neoplasm were subjected to surgery after an erroneous CMR diagnosis of a benign neoplasm.
Discussion
The present study showed that a comprehensive CMR evaluation of tumour morphology, tissue composition, and perfusion in conjunction with information on tumour spread and operability can adequately direct patients to the appropriate therapeutic strategy. In particular, CMR excelled in its capacity to risk stratify patients by confidently excluding masses or reclassifying them as anatomical variants and by distinguishing benign from malignant processes. Although enhanced soft tissue contrast in various sequences increased depiction, delineation, and enhanced stratification of the masses compared with echocardiography, CMR faced limitations in depicting small valvular lesions and in tissue characterization at the histological level. With a incidence of 0.03% (primary tumours) to 2.0% (all tumours) in autopsy series 11 -13 and 0.15% in echocardiographic series, 14 cardiac tumours are rare entities in clinical cardiology that pose particular challenges to diagnostic cardiac imaging. Cardiac tumours have a broad differential diagnosis and need to be distinguished from non-neoplastic masses. In addition, treatment is significantly directed by symptoms, haemodynamic, embolic, or arrhythmic implications, and by neoplastic nature, type, dissemination, or operability of the mass. 1 -3,15 Optimal tumour characterization for clinical management therefore includes information on local tumour topology and invasiveness, and at best delivers some degree of tissue characterization. Being non-invasive, cost-effective, quick, and widely available, echocardiography is usually employed as first-line imaging modality. 15, 16 In fact, many masses-in the present study up to 50%-are coincidently detected during examinations for unrelated conditions. This technique was also found to have a primary diagnostic role in the detection of valvular lesions and to allow for a relatively confident diagnosis of typically localized myxomas. Incomplete or inadequate acoustic windows and rather poor tissue contrast restrict the capacity of echocardiography to properly evaluate and delineate peri-and paracardiac lesions 17 and to adequately differentiate among various tissue types. 18 The unrestricted field of view combined with superior soft tissue and blood pool contrast in various unenhanced CMR sequences renders distinct advantages under such circumstances. 4, 5 Contrast agents further enhance detection and delineation of masses when distinction of intramural tumours from the normal myocardium still remains equivocal and are invaluable in the detection of intracavitary thrombi. 8, 10, 18, 19 Thus, paracardiac, metastatic, and infiltrative processes may be assessed more readily or can inversely be excluded with more confidence by CMR. Indeed, referrals because of ambivalent echocardiographic findings comprised .30% of the CMR examinations and mostly related to intramural, retrocardial, or pericardial masses that could be confidently excluded by subsequent CMR. 20, 21 In a study by Winkler and Higgins 21 including 34 patients followed for up to 2 years, CMR could exclude or reclassify cardiac masses to anatomic variants or other abnormalities in up to 58 and 20% of the masses suspected on echocardiography, respectively. The excellent outcome under long-term conservative treatment observed in our study provides evidence that refraining from surgical exploration or intervention in such patients is both justified and safe. In the case of suspicious small valvular lesions like fibroelastoma, CMR may however perform suboptimally 22 and rather an echocardiography-guided management, although often not surgical in nature, appears warranted. Only a limited number of studies have systematically examined the value of various pulse sequences and/or contrast enhancement techniques in differentiating cardiac masses based on their tissue characteristics. 6 -8 In the differentiation between malignant and benign lesions, the present data and a previous study by Hoffmann et al. 7 indicated an overall accuracy of 90-95% for an integrative CMR assessment of morphological features and signal characteristics. Yet, no single CMR feature was both highly specific and highly sensitive in the differentiation between benign or malignant cardiac and paracardiac masses. In particular, morphological features, such as right-sided or paracardiac location, invasive or compressive growth patterns and presence of pericardial effusion, emerged as single predictors for malignancy, 7,23 whereas individual signal characteristics had little predictive value per se. As illustrated in Table 1 , this is partially explained by the high variability of single T1 and T2 signal characteristics among the various benign and malignant masses, which used in isolation consequently provide little information on the biological nature of the tumour. Nevertheless, confident CMR characterization is possible for some tumours and masses homogeneously composed of a tissue type with a more or less characteristic morphological and signal 'fingerprint', such as fat and lipomas, fibrosis and fibromas, and pericardial cysts. 5, 7, 8 Fat, for example, has very constant T1 and T2 signal properties that can be suppressed in a selective manner by fatspecific saturation prepulses. In the present population, these unique signal properties allowed for a confident risk stratification and conservative management of many patients with benign fatty masses. As opposed to homogeneous tissue characteristics in the above-mentioned conditions, a heterogeneous signal composition of the tissue indicative of focal haemorrhage, necrosis, calcification, or regional myxoid degeneration has been reported as a sensitive feature of malignancy. 7, 8 It has, however, also been consistently reported in myxomas 7, 24 and accordingly did not emerge as a distinctive feature in the present study. On the same grounds, post-contrast enhancement has been proposed as a feature of malignancy. 7, 8, 23 Late enhancement of myxoid stroma or necrotic areas within myxomas is, however, also rather common, amounting up to 40% in our study. 6 -8 Intense, inhomogeneous enhancement early after contrast is also seen in benign cardiac haemangiomas. 25 Perfusion imaging aims at depicting tumour perfusion and capillary density by assessing the contrast wash-in dynamics at first passage. Fibroelastoma and thrombus are principally avascular masses and many benign tumours (e.g. fibroma, lipoma) are rather sparsely vascularized compared with the faster growing malignant tumours, with the noticeable exception of haemangioma. 1 The importance of first-pass perfusion imaging in tumour characterization has not been investigated before. In the subset of patients subjected to this technique, malignant lesions tended to display noticeable perfusion more frequently. Contrary to late enhancement, signal increase in first-pass contrast passage was rare in myxomas (16%). This potential benefit over late enhancement imaging requires confirmation in larger studies. Finally, integration of imaging data with epidemiological probability and clinical data is an integral part of tumour stratification and clinical decision-making in daily practice. All patients with cardiac metastasis in our study had a history of extracardiac metastatic disease. On the other hand, CMR confidently differentiated lipomatous hypertrophy from metastatic infiltration and accurately diagnosed a few myxomas in cancer patients, while identifying cardiac infiltration in others. This highlights that CMR may convey independent information for differential diagnosis and operative planning in many patients. 7, 20 Most importantly, in patients managed conservatively based on the CMR diagnosis, no tumour-related deaths occurred other than in those receiving palliative care because of documented metastatic disease. As such, from the perspective of CMR-guided therapy management ('intention to treat'), CMR was found accurate.
Limitations
It should be acknowledged that the eventual study outcome represents the result of a staged approach in which echocardiography was the gatekeeper to most of the CMR examinations. In the absence of a comparison free of potential referral bias, the additive value of CMR to echocardiography and clinical assessment remains difficult to establish. As either individual technique was found to yield specific limitations and to have some complementary assets, such combined approach may currently remain warranted. Another acknowledged limitation of the study is its retrospective design; despite all efforts to improve the consistency in CMR interpretation by pre-specified scoring systems and review sessions blinded from other than the referral information, this inherently carries the risk of somewhat overestimating the favourable results for CMR. With technological advances, some typical CMR parameters (e.g. late enhancement and perfusion) have become readily feasible by echocardiography and/or CT and need to be explored in the future. More in general, also for most of the contemporary CMR sequences and for contrast applications in particular, tumour characteristics reported in previous studies remain scattered and scarce. Although our study adds more data to this field and is encouraging enough to endorse CMR as a decisive imaging modality in this orphan disease, prospective multicentre registries and/or studies 26 should follow to underscore the results.
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